[go: up one dir, main page]

CA2352486A1 - Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative - Google Patents

Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative Download PDF

Info

Publication number
CA2352486A1
CA2352486A1 CA002352486A CA2352486A CA2352486A1 CA 2352486 A1 CA2352486 A1 CA 2352486A1 CA 002352486 A CA002352486 A CA 002352486A CA 2352486 A CA2352486 A CA 2352486A CA 2352486 A1 CA2352486 A1 CA 2352486A1
Authority
CA
Canada
Prior art keywords
cell
cells
agent
leu
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352486A
Other languages
English (en)
Inventor
Gregory J. Hannon
David H. Beach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENETICA Inc
Cold Spring Harbor Laboratory
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2352486A1 publication Critical patent/CA2352486A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes et des réactifs destinés à prolonger la durée de vie, c'est-à-dire, le nombre de divisions mitotiques d'une cellule. D'une manière générale, la méthode de l'invention se base sur l'activation d'une activité de télomérase et l'inhibition d'une voie Rb/p16 et/ou d'une voie p53.
CA002352486A 1998-11-25 1999-11-24 Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative Abandoned CA2352486A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10989198P 1998-11-25 1998-11-25
US60/109.891 1998-11-25
US12054999P 1999-02-17 1999-02-17
US60/120,549 1999-02-17
PCT/US1999/027907 WO2000031238A2 (fr) 1998-11-25 1999-11-24 Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative

Publications (1)

Publication Number Publication Date
CA2352486A1 true CA2352486A1 (fr) 2000-06-02

Family

ID=26807479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352486A Abandoned CA2352486A1 (fr) 1998-11-25 1999-11-24 Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative

Country Status (6)

Country Link
EP (1) EP1133552A2 (fr)
JP (1) JP2002530436A (fr)
AU (1) AU2156600A (fr)
CA (1) CA2352486A1 (fr)
IL (1) IL143328A0 (fr)
WO (1) WO2000031238A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1170378A1 (fr) * 2000-06-26 2002-01-09 Boehringer Ingelheim International GmbH Procédé pour évaluer l'effet du thérapies de cancer
DE10054974A1 (de) * 2000-11-06 2002-06-06 Epigenomics Ag Diagnose von mit Cdk4 assoziierten Krankheiten
AU2002242854A1 (en) 2001-03-21 2002-10-03 Geron Corporation Use of telomerase reverse transcriptase to create homozygous knockout animals
AU2002342613A1 (en) 2001-05-09 2002-11-25 Geron Corporation Treatment for wounds
AU2003208580A1 (en) * 2002-02-05 2003-09-02 Technion Research And Development Foundation Ltd Lineage committed stem cells selected for telomerase promoter activity
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
JPWO2004076483A1 (ja) * 2003-02-26 2006-06-01 独立行政法人科学技術振興機構 癌細胞のアポトーシスを誘導する転写因子
EP1626714B1 (fr) 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Urees de diaryle pour des maladies mediees par le recepteur du facteur de croissance derive des plaquettes
EA009442B1 (ru) 2003-06-23 2007-12-28 Герон Корпорейшн Композиции и способы увеличения активности теломеразы
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
EP1663978B1 (fr) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
PL1799269T3 (pl) * 2004-09-28 2017-01-31 Quark Pharmaceuticals, Inc. Oligorybonukleotydy i sposoby ich zastosowania do leczenia łysienia, ostrej niewydolności nerek i innych chorób
EP1880733A4 (fr) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Procede pour prolonger la duree de vie d'animaux ou de l'humain
JP2006325444A (ja) * 2005-05-24 2006-12-07 Toyobo Co Ltd 細胞増殖培地
AU2006311637A1 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Methods and compositions for modulation of stem cell aging
JP5372769B2 (ja) 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
ES2661310T3 (es) 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
SI2437606T1 (sl) 2009-05-18 2016-10-28 Telomerase Activation Sciences, Inc. Sestavki in postopki za povečanje telomerazne aktivnosti
CN108383894A (zh) 2010-02-16 2018-08-10 阿尔特公司 多肽及其应用
GB201202228D0 (en) * 2012-02-08 2012-03-28 Queen Mary & Westfield College Reversal of replicative senescence
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
US11525146B2 (en) 2017-01-09 2022-12-13 Oisin Biotechnologies, Inc. Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
WO2019166702A1 (fr) 2018-02-28 2019-09-06 Hagalife Utilisation d'un procédé d'irradiation flash pour augmenter la longévité et/ou pour retarder les effets du vieillissement chez les mammifères
JP7592493B2 (ja) 2018-04-18 2024-12-02 オイシン バイオテクノロジーズ,インク. 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
CN113774020B (zh) * 2021-08-24 2023-04-14 河北朋和生物科技有限公司 一种脂肪间充质干细胞库的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2080158A1 (fr) * 1991-10-11 1993-04-12 Scott A. Biller Methode d'inhibition de la transformation neoplastique des cellules provoquee par les oncogenes ras au moyen de bisphosphonates ou d'analogues de ces derniers
CA2118985A1 (fr) * 1993-04-02 1994-10-03 Dinesh V. Patel Inhibiteurs heterocycliques de la farnesyl proteine transferase
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6037136A (en) * 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5624936A (en) * 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998037181A2 (fr) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Gene de sous-unite catalytique de telomerase et proteine codee
JP2002500040A (ja) * 1998-01-12 2002-01-08 コールド スプリング ハーバー ラボラトリー 細胞の寿命の延長、方法および試薬
AU760252B2 (en) * 1998-01-30 2003-05-08 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents

Also Published As

Publication number Publication date
EP1133552A2 (fr) 2001-09-19
AU2156600A (en) 2000-06-13
WO2000031238A2 (fr) 2000-06-02
WO2000031238A3 (fr) 2000-11-09
JP2002530436A (ja) 2002-09-17
IL143328A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
CA2352486A1 (fr) Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative
AU759437B2 (en) Extension of cellular lifespan, methods and reagents
Fujio et al. Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival
Guerra et al. Protein kinase CK2 and its role in cellular proliferation, development and pathology
US20080227738A1 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
Galderisi et al. The retinoblastoma gene is involved in multiple aspects of stem cell biology
US20040002447A1 (en) Induction of insulin expression
AU724324B2 (en) p16 expression constructs and their application in cancer therapy
Gasdaska et al. Human thioredoxin reductase gene localization to chromosomal position 12q23–q24. 1 and mRNA distribution in human tissue
KR101169980B1 (ko) 심근 세포의 증식 방법
AU760252B2 (en) Modulation of cell proliferation, methods and reagents
CA2447703C (fr) Procede permettant de faire proliferer des cellules a differenciation terminal et vecteur de recombinaison pour la mise en oeuvre de ce procede
US7795032B2 (en) Methods for proliferating cardiomyocytes and recombinant vectors therefor
WO2010053199A1 (fr) Composition pharmaceutique destinée au traitement d’un cancer de la prostate et méthode de traitement d’un cancer de la prostate
KR20180121046A (ko) Chip를 유효성분으로 포함하는 oct4의 발현을 억제하거나 유비퀴틴화를 촉진하기 위한 생물학적 조성물
EP4043549A2 (fr) Composition de milieu pour améliorer l'activité de la protéine wnt
Darp Insights into the Role of Oncogenic BRAF in Tetraploidy and Melanoma Initiation
Trembley Rat cyclin B1 gene expression and regulation in liver
Luchin Regulation of Osteoclast differentiation by Microphthalmia-associated transcription factor
Shultz The Regulation of Alternative Splicing by Oncogenic Signaling Pathways.
Rhoads Translational control and the cell cycle
Bryan Regulation of the Rho-family of small GTPases by GEFT
Westbrook III Mislocalization of Cip/Kip CDK inhibitors and dysregulation of cellular proliferation by the HPV16 E7 oncoprotein
Lawlor Studies of signaling pathways that regulate Ewing tumour cell growth in vitro
Melkoumian Pharmacological regulation of c-myc gene expression in human breast cancer cells

Legal Events

Date Code Title Description
FZDE Discontinued